Suzhou Pharma Services

suzhoupharma.com

Suzhou Pharma Services, a division of Amerigen Pharmaceuticals, is a contract development and manufacturing organization focused on oral solid dose forms. With US offices located in East Brunswick, NJ and the primary manufacturing site located in Suzhou, China, we are licensed by the Chinese sFDA and the US FDA. The management team in China and the USA is comprised of highly experienced, Western trained leaders, averaging 20+ years experience with multi-national branded and generic pharmaceutical companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

news image

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More

PHARMA TECH

BRUKER LAUNCHES NEW TIMSTOF-BASED MALDI PHARMAPULSE® SOLUTION FOR LABEL-FREE HTS IN DRUG DISCOVERY

Bruker Corporation | February 07, 2022

news image

At the SLAS2022 International Conference and Exhibition, Bruker Corporation announced the launch of its timsTOF MALDI PharmaPulse® (timsTOF MPP) system, a groundbreaking new high-end solution for unbiased, deep HTS and uHTS based on label-free mass spectrometry. The new timsTOF® MPP is now the flagship of Bruker´s MALDI PharmaPulse product family which became a game changer in the HTS market with the launch of the rapifleX MPP, a MALDI-TOF-based label-free uHTS solut...

Read More

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

news image

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More

PHARMA TECH

SPECIFICA ANNOUNCES ANTIBODY DISCOVERY PLATFORM TRANSFER AGREEMENT WITH SANOFI

Specifica | June 03, 2022

news image

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, announced an agreement with the global healthcare company Sanofi under which Specifica’s patented Generation 3 Antibody Discovery Platform will be transferred to Sanofi. The comprehensive technology transfer package will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs. “<...

Read More
news image

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More
news image

PHARMA TECH

BRUKER LAUNCHES NEW TIMSTOF-BASED MALDI PHARMAPULSE® SOLUTION FOR LABEL-FREE HTS IN DRUG DISCOVERY

Bruker Corporation | February 07, 2022

At the SLAS2022 International Conference and Exhibition, Bruker Corporation announced the launch of its timsTOF MALDI PharmaPulse® (timsTOF MPP) system, a groundbreaking new high-end solution for unbiased, deep HTS and uHTS based on label-free mass spectrometry. The new timsTOF® MPP is now the flagship of Bruker´s MALDI PharmaPulse product family which became a game changer in the HTS market with the launch of the rapifleX MPP, a MALDI-TOF-based label-free uHTS solut...

Read More
news image

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More
news image

PHARMA TECH

SPECIFICA ANNOUNCES ANTIBODY DISCOVERY PLATFORM TRANSFER AGREEMENT WITH SANOFI

Specifica | June 03, 2022

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, announced an agreement with the global healthcare company Sanofi under which Specifica’s patented Generation 3 Antibody Discovery Platform will be transferred to Sanofi. The comprehensive technology transfer package will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs. “<...

Read More